ImmunoGen Provides Positive Results For Trastuzumab-DM1 Study
ImmunoGen has presented positive clinical data on trastuzumab-DM1 (T-DM1), at the 32nd Annual San Antonio Breast Cancer Symposium. T-DM1 comprises ImmunoGen’s DM1 cancer-cell killing agent linked to the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.